CORT
Corcept Therapeutics Incorporated
CORT's fundamentals are strong, but it looks expensive: trading at 58x earnings, about twice its usual 29x. Analysts expect strong earnings growth, though they disagree widely on how much.
CORT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
CORT's revenue, profitability, cash flow and balance sheet are all currently strong.
CORT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 17x | $73.71 | — |
| Cheap | 22x | $27.59 | -63% |
| Fair | 29x | $36.55 | -50% |
| Current | 58x | $73.71 | — |
| Expensive | 59x | $75.21 | +2% |
Historical ranges are pointers, not guarantees.
CORT's PE is in its expensive range at 58x. If earnings grow as analysts expect, today's price would be 17x next year's earnings, in its cheap range.
CORT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for CORT, with profitability improving. However, they disagree widely on these estimates.
CORT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.42 | +248% |
| Q3 2026 | $1.27 | +46% |
| Q2 2026 | $0.42 | -63% |
| Q1 2026 | $0.35 | -70% |
| Q4 2025 | $0.82 | -33% |
| Q3 2025 | $0.87 | -30% |
| Q2 2025 | $1.12 | 0% |
| Q1 2025 | $1.15 | +9.5% |
| Q4 2024 | $1.23 | +31% |
CORT earned $1.27 per share over the past year, up 46% from the year before.
CORT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $340.5M | +64% |
| Q2 2026 | $256.1M | +32% |
| Q1 2026 | $164.9M | +4.9% |
| Q4 2025 | $202.1M | +11% |
| Q3 2025 | $207.6M | +14% |
| Q2 2025 | $194.4M | +19% |
| Q1 2025 | $157.2M | +7.1% |
| Q4 2024 | $181.9M | +34% |
CORT's revenue has grown year over year for 22 quarters in a row: $340M last quarter, up 64% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | +29 points |
| Q2 2026 | 16% | +2.4 points |
| Q1 2026 | -30% | -32 points |
| Q4 2025 | 2.2% | -12 points |
| Q3 2025 | 4.9% | -21 points |
| Q2 2025 | 14% | -8 points |
| Q1 2025 | 2.2% | -18 points |
| Q4 2024 | 14% | -9.5 points |
CORT's operating margin was 34% last quarter, up 29 points from the same quarter a year ago.
CORT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $142.2M | +161% |
| Q2 2026 | $31M | -29% |
| Q1 2026 | -$17M | -438% |
| Q4 2025 | $38.4M | -35% |
| Q3 2025 | $54.5M | -25% |
| Q1 2025 | $5M | -79% |
| Q4 2024 | $59.2M | +905% |
| Q3 2024 | $72.2M | +37% |
CORT generated $195M in free cash flow over the past year, up 20% from the year before.
CORT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +4.8M shares |
| 1 year | +3.1% | +3.8M shares |
| 3 years | +11% | +12.1M shares |
| 5 years | -1.5% | -1.9M shares |
| Available history | +0.5% | +635K shares |
CORT has 123M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5.7M |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $42.5M |
| Q2 2025 | $103M |
| Q1 2025 | $27.4M |
| Q4 2024 | — |
CORT has spent almost nothing on buybacks in the past year.
CORT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -13.2x | Net Cash |
| Q4 2025 | -2.6x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -0.8x | Net Cash |
| Q4 2024 | -0.9x | Net Cash |
| Q3 2024 | -1.0x | Net Cash |
CORT has more cash than debt.
CORT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.9 | Neutral |
| Stochastic | 3.4 | Oversold |
CORT's weekly RSI is 39 (neutral) and its Stochastic is 3 (oversold).
CORT PE vs Healthcare Sector
| Metric | CORT | Sector median | Relative |
|---|---|---|---|
| PE | 58x | 26x | 125% above |
| PE % | 82 | 29 | 53 pts above |
CORT is trading at 58x earnings, a 125% premium to the Healthcare sector's median of 26x.
CORT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $97.1 | 24% below |
| 20 week MA | $102.8 | 28% below |
| 50 week MA | $73.4 | 0.4% above |
| 100 week MA | $71.2 | 3.6% above |
| 200 week MA | $50.5 | 46% above |
CORT has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 46% above its 200-week average.
CORT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.3 | $27.2 | +121% |
| 2021 | $27.2 | $19.9 | -27% |
| 2022 | $19.9 | $20.7 | +4% |
| 2023 | $20.7 | $32.5 | +57% |
| 2024 | $32.5 | $52.5 | +62% |
| 2025 | $52.5 | $82.7 | +58% |
| 2026 YTD | $82.7 | $73.7 | -11% |
CORT has finished higher in five of the last six years, four of them by more than 50%. It's down 11% so far in 2026.